Clarify Remdesivir and Convalescent Plasma Use for COVID-19
You'll hear buzz about emergency use authorizations (EUAs) for remdesivir and convalescent plasma to treat COVID-19.
Remdesivir (Veklury). FDA is expanding the EUA to include ALL hospitalized patients with suspected or confirmed COVID-19.
But there currently isn't enough evidence to be certain of a benefit in nonsevere patients...and a 5-day course costs over $3,000.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive